Differential cerebrospinal fluid reactivity to pfdn5-alpha for detection of b-cell acute lymphoblastic central nervous system leukemia
Source:Amrita Vishwa Vidypeetham, Volume WO2014108855 (A1), Number PCT/IB2014/058167, India (2014)
A method of managing treatment in a patient with B-cell acute lymphoblastic leukemia (B-ALL) for central nervous system (CNS) leukemia is disclosed. The method comprises obtaining cerebrospinal fluid (CSF) from the patient, obtaining a cell proteome including PFDN5-[alpha] from the patient, detecting reactivity of CSF against the PFDN5-[alpha], comparing reactivity profile of CSF against the PFDN5-[alpha] at diagnosis and during treatment, and determining the status of proliferation of leukemia in the patient depending on the comparison. The method further comprises treating the patient for CNS leukemia based on the status of proliferation.
Cite this Research Publication
Related Research Publications
- Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases
- A clinicopathological correlation of acute leukaemias in relation to immunophenotyping and cytogenetics
- Clinical profile and treatment outcome of febrile infection-related epilepsy syndrome in South Indian children.
- A novel unbiased proteomic approach to detect the reactivity of cerebrospinal fluid in neurological diseases
- Quantitation of Fc receptor-bearing T-lymphocytes (TG and TM) in oral cancer